DOCSLIB.ORG

Australian Public Assessment Report for Trastuzumab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Australian Public Assessment Report for Trastuzumab Australian Public Assessment Report for Trastuzumab Proprietary Product Name: Ogivri Sponsor: Alphapharm Pty Ltd March 2020 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA. Copyright © Commonwealth of Australia 2020 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[email protected]>. AusPAR OGIVRI - Trastuzumab - Alphapharm Pty Ltd - PM-2017-01084-1-4 2020 Page 2 of 30 FINAL 18 March Therapeutic Goods Administration Contents Common abbreviations _____________________________________________________ 4 I. Introduction to product submission ____________________________________ 6 Submission details ____________________________________________________________________ 6 Product background __________________________________________________________________ 7 Regulatory status _____________________________________________________________________ 8 Product Information__________________________________________________________________ 8 II. Registration time line ____________________________________________________ 8 III. Overall conclusion and risk/benefit assessment ___________________ 9 Introduction ___________________________________________________________________________ 9 Quality ________________________________________________________________________________ 13 Nonclinical ___________________________________________________________________________ 14 Clinical ________________________________________________________________________________ 14 Risk management plan ______________________________________________________________ 25 Risk-benefit analysis ________________________________________________________________ 27 Outcome ______________________________________________________________________________ 28 Attachment 1. Product Information _____________________________________ 29 AusPAR OGIVRI - Trastuzumab - Alphapharm Pty Ltd - PM-2017-01084-1-4 Page 3 of 30 FINAL 18 March 2020 Therapeutic Goods Administration Common abbreviations Abbreviation Meaning ADA Anti-drug antibody/antibodies ADCC Antibody-dependent cell-mediated cytotoxicity AE Adverse event ARTG Australian Register of Therapeutic Goods AUC Area under the curve or area under the serum concentration versus time curve AUC0- Area under the curve or area under the serum concentration ∞ versus time curve from time 0 (dosing) extrapolated to infinity AUC0-last Area under the curve or area under the serum concentration versus time curve from time 0 (dosing) to last measured concentration CHMP Committee for Medicinal Products for Human Use (EU) CI Confidence interval Cmax Maximum observed serum concentration after IV infusion (just after end of infusion) ECOG Eastern Cooperative Oncology Group EMA European Medicines Agency (EU) ErbB-2 Human epidermal growth factor receptor 2 (also known as HER2) EU European Union FDA Food and Drug Administration (US) GMP Good Manufacturing Practice HER2 Human epidermal growth factor receptor 2 HFI Hereditary fructose intolerance ICH International Conference on Harmonisation IHC Immunohistochemistry IM Intramuscular ITT Intention-to-treat AusPAR OGIVRI - Trastuzumab - Alphapharm Pty Ltd - PM-2017-01084-1-4 Page 4 of 30 FINAL 18 March 2020 Therapeutic Goods Administration Abbreviation Meaning IV Intravenous LVEF Left ventricular ejection fraction (via echocardiography) MAA Marketing Authorisation Application mAbs Monoclonal antibodies ODAC Oncologic Drugs Advisory Committee (US) ORR Objective response rate OS Overall survival pCR Pathological complete response PD Pharmacodynamic(s) PE Point estimate PEG Polymers of ethylene glycol PFS Progression free survival PI Product Information PK Pharmacokinetic(s) popPK Population pharmacokinetic(s) PRAC Pharmacovigilance Risk Assessment Committee (EU) RECIST Response Evaluation Criteria in Solid Tumours RMP Risk management plan SAE Serious adverse event SmPC Summary of Product Characteristics (EU) TEAE Treatment-emergent adverse event TTP Time to tumour progression US(A) United States (of America) AusPAR OGIVRI - Trastuzumab - Alphapharm Pty Ltd - PM-2017-01084-1-4 Page 5 of 30 FINAL 18 March 2020 Therapeutic Goods Administration I. Introduction to product submission Submission details Type of submission: Biosimilar Decision: Approved Date of decision: 5 December 2018 Date of entry onto ARTG: 11 December 2018 ARTG numbers: 288222, 288223 No ‚Black Triangle Scheme Active ingredient: Trastuzumab Product name: Ogivri Sponsor’s name and address: Alphapharm Pty Ltd PO Box R1462 Royal Exchange NSW 1225 Dose forms: Powder for injection 150 mg vial; and Powder for injection 440 mg vial with bacteriostatic water for injection vial Strength: 150 mg and 400 mg Container: Vial Pack size: 1 Approved therapeutic use: Early Breast Cancer Ogivri is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy. Locally Advanced Breast Cancer Ogivri is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant OGIVRI. Metastatic Breast Cancer Ogivri is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: AusPAR OGIVRI - Trastuzumab - Alphapharm Pty Ltd - PM-2017-01084-1-4 Page 6 of 30 FINAL 18 March 2020 Therapeutic Goods Administration a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer. Advanced Gastric Cancer Ogivri is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro- oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Routes of administration: Intravenous Dosage: The dosage is the same as for the innovator product Herceptin trastuzumab. Product background This AusPAR describes the application by Alphapharm Pty Ltd (the sponsor) to register Ogivri trastuzumab, 150 mg powder for injection vial, and, 440 mg powder for injection vial with bacteriostatic water for injection vial for the following indication: Early Breast Cancer Ogivri is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy. Locally Advanced Breast Cancer Ogivri is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri. Metastatic Breast Cancer Ogivri is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: a) as monotherapy for the treatment of those patients
Load more

Recommended publications
  • Activity of Rituximab and Ofatumumab Against Mantle
    ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT CYTOTOXICITY (CDC)AND ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY ASSAYS(ADCC) Dr. Gopichand Pendurti M.B.B.S Mentor: Dr. Francisco J. Hernandez-Ilizaliturri MD Overview of presentation •Introduction to mantle cell lymphoma. •Concept of minimal residual disease. •Anti CD 20 antibodies. •51Cr release assays. •Flow cytometry on cell lines. •Results. •Future. MANTLE CELL LYMPHOMA •Mantle cell lymphoma is characterized by abnormal proliferation of mature B lymphocytes derived from naïve B cells. •Constitutes about 5% of all patients with Non Hodgkin's lymphoma. •Predominantly in males with M:F ratio 2.7:1 with onset at advanced age (median age 60yrs). •It is an aggressive lymphoma with median survival of patients being 3-4 years. •Often presents as stage III-IV with lymphadenopathy, hepatosplenomegaly, gastrointestinal involvement, peripheral blood involvement. Pedro Jares, Dolors Colomer and Elias Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nature revision of cancer 2007 October:7(10):750-62 •Genetic hallmark is t(11:14)(q13:q32) translocation leading to over expression of cyclin D1 which has one of the important pathogenetic role in deregulating the cell cycle. •Other pathogentic mechanisms include molecular and chromosomal alterations that Target proteins that regulate the cell cycle and senecense (BMI1,INK4a,ARF,CDK4 AND RB1). Interfere with cellular
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • B-Cell Targets to Treat Antibody-Mediated Rejection In
    Muro et al. Int J Transplant Res Med 2016, 2:023 Volume 2 | Issue 2 International Journal of Transplantation Research and Medicine Commentary: Open Access B-Cell Targets to Treat Antibody-Mediated Rejection in Transplantation Manuel Muro1*, Santiago Llorente2, Jose A Galian1, Francisco Boix1, Jorge Eguia1, Gema Gonzalez-Martinez1, Maria R Moya-Quiles1 and Alfredo Minguela1 1Immunology Service, University Clinic Hospital Virgen de la Arrixaca, Spain 2Nephrology Service, University Clinic Hospital Virgen de la Arrixaca, Spain *Corresponding author: Manuel Muro, PhD, Immunology Service, University Clinic Hospital “Virgen de la Arrixaca”, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain, Tel: 34-968-369599, E-mail: [email protected] Antibody-mediated rejection (AMR) in allograft transplantation APRIL (a proliferation-inducing ligand). These co-activation signals can be defined with a rapid increase in the levels of specific are required for B-cell differentiation into plasma cell and enhancing serological parameters after organ transplantation, presence of donor their posterior survival and are a key determinant of whether specific antibodies (DSAs) against human leukocyte antigen (HLA) developing B-cells will survive or die during the establishment molecules, blood group (ABO) antigens and/or endothelial cell of immuno-tolerance [5,6]. Important used agents commercially antigens (e.g. MICA, ECA, Vimentin, or ETAR) and also particular available are Tocilizumab (anti-IL6R) and Belimumab (BAFF). histological parameters [1,2]. If the AMR persists or progresses, the The receptors of BAFF and APRIL could also be important as treatment to eliminate the humoral component of acute rejection eventual targets, for example BAFF-R, TACI (transmembrane include three sequential steps: (a) steroid pulses, antibody removal activator and calcium modulator and cyclophyllin ligand interactor) (plasma exchange or immuno-adsorption) and high doses of and BCMA (B-cell maturation antigen).
    [Show full text]
  • Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 In
    Journal of Nuclear Medicine, published on January 18, 2018 as doi:10.2967/jnumed.117.203299 Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts Jason T. Yoon†,1, Mark S. Longtine†,1, Bernadette V. Marquez-Nostra1,2, and Richard L. Wahl1 †Contributed equally. 1Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO 63110. 2Current address: Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University, PO Box 208048, New Haven, CT, 056520. First author (Jason Yoon) address: as noted above. Phone, 714-364-7560; E-mail, [email protected] For correspondence or reprints contact: Richard Wahl, MD Washington University School of Medicine, Department of Radiology, Campus Box 8131, 660 S. Euclid Ave, St. Louis, MO 63110 Telephone: (314) 362-7100, Fax: (314)747-4189 Email: [email protected] Financial Support: This study was funded, in part, by Radiological Society of North America Education and Research Foundation Medical Student research award, RMS1646, to JTY and RLW. BVMN is supported by the National Institutes of Health (grant 1K99CA201601). Word Count of Manuscript: 4,994 Running Title: Next-Generation 89Zr-Anti-CD20 mAbs ABSTRACT Radioimmunotherapies with monoclonal antibodies (mAbs) to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but United States Food and Drug Administration (FDA)-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting re-dosing. The FDA recently approved two unlabeled anti-CD20 monoclonal antibodies, obinutizumab and ofatumumab, termed "next generation" as they are humanized (obinituzumab) or fully human (ofatumumab), thus potentially allowing a greater potential for re-dosing than with previous generation anti-CD20 antibodies, including rituximab (chimeric) and tositumumab (murine) which contain more murine peptide sequences.
    [Show full text]
  • One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 43, No. 10, 539-549, October 2011 One target, different effects: a comparison of distinct therapeutic antibodies against the same targets Hyunbo Shim ple, four antibodies against TNF-α have been approved by the FDA -- infliximab, adalimumab, golimumab, and Department of Life Science certolizumab pegol -- with many more in clinical and Division of Life and Pharmaceutical Sciences preclinical development. The situation is similar for Ewha Womans University HER2, CD20, EGFR, and VEGF, each having one or Seoul 120-750, Korea more approved antibodies and many more under Correspondence: Tel, 82-2-3277-4240; development. This review discusses the different bind- Fax, 82-2-3277-3760; E-mail, [email protected] ing characteristics, mechanisms of action, and bio- http://dx.doi.org/10.3858/emm.2011.43.10.063 logical and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and Accepted 2 August 2011 provides insights into the development of therapeutic Available Online 3 August 2011 antibodies. Abbreviations: ADC, antibody-drug conjugate; ADCC, antibody- dependent cellular cytotoxicity; CD20, cluster of differentiation Keywords: antibodies, monoclonal; antigens, CD20; 20; CDC, complement dependent cytotoxicity; CLL, chronic pharmacology; receptor, epidermal growth factor; re- lymphocytic leukemia; ECD, extracellular domain; EGFR, epi- ceptor, erbB-2; tumor necrosis factor-α dermal growth factor receptor; EpCAM, epithelial cell adhe- sion molecule; FcγR, Fc gamma receptor;
    [Show full text]
  • Hodgkin's Lymphoma Unresponsive to Rituximab Or a Rituximab
    Clinical Development GSK1841157 Protocol OMB110918 / NCT01077518 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non- Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Authors Document type Amended Protocol Version EUDRACT number 2008-004177-17 Version number 11 Development phase III Document status Final Release date 13-Apr-2017 Novartis internal reference number COMB157E2301 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Novartis Confidential Page 2 Amended Protocol Version 11 Clean Protocol No. COMB157E2301/OMB110918 Amendment 9 (13-Apr-2017) Amendment rationale The purpose of amendment 9 is to revise the total number of events required for the primary analysis of the primary end point PFS. The primary analysis was planned after reaching 259 PFS events as determined by an Independent Review Committee (IRC). Based on the current status of the study and PFS event count by IRC, it is highly unlikely that the 259 PFS events will be achieved. The study has been ongoing since September 2010 when the first patient was enrolled and the study sponsorship changed in February 2016 from GSK to Novartis (Amendment 8 , dated 18Mar2016). Per protocol, Interim Analysis for efficacy and futility and IDMC review occurred (22Feb2016) after 180 PFS events by IRC were reached (31Oct2015). IDMC recommended to continue the study without changes. The interim analysis of PFS was performed by an independent Statistical Data Analysis Centre. As per IDMC charter, unblinded results were not communicated to the sponsor in order to maintain the integrity of the trial.
    [Show full text]
  • Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
    Published OnlineFirst July 2, 2010; DOI: 10.1158/1078-0432.CCR-10-0570 Published OnlineFirst on August 24, 2010 as 10.1158/1078-0432.CCR-10-0570 Report from the FDA Clinical Cancer Research U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab Steven J. Lemery1, Jenny Zhang2, Mark D. Rothmann2, Jun Yang3, Justin Earp3, Hong Zhao3, Andrew McDougal1, Anne Pilaro1, Raymond Chiang1, Joseph E. Gootenberg1, Patricia Keegan1, and Richard Pazdur1 Abstract Purpose: To describe the data and analyses that led to the U.S. Food and Drug Administration (FDA) approval of ofatumumab (Arzerra, GlaxoSmithKline) for the treatment of patients with chronic lympho- cytic leukemia (CLL) refractory to fludarabine and alemtuzumab. Experimental Design: The FDA reviewed the results of a planned interim analysis of a single-arm trial, enrolling 154 patients with CLL refractory to fludarabine, and a supportive dose-finding, activity-estimat- ing trial in 33 patients with CLL. Patients in the primary efficacy study received ofatumumab weekly for eight doses, then every 4 weeks for an additional four doses; patients in the supportive trial received four weekly doses. In the primary efficacy study, endpoints were objective response rate and response duration. Results: For regulatory purposes, the primary efficacy population consisted of 59 patients with CLL refractory to fludarabine and alemtuzumab. In this subgroup, the investigator-determined objective response rate was 42% [99% confidence interval (CI), 26–60], with a median duration of response of 6.5 months (95% CI, 5.8–8.3); all were partial responses.
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • Ofatumumab in RMS • BTD for Janssen’S JNJ-61186372 (Amivantamab) • Anthony Pagano Appointed to CFO and Anthony Mancini Appointed to Newly Created Position of COO
    Quarter End Results Period Ended March 31, 2020 Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors.
    [Show full text]
  • The Role of Monoclonal Antibodies in the Management of Leukemia
    Pharmaceuticals 2010, 3, 3258-3274; doi:10.3390/ph3103258 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Role of Monoclonal Antibodies in the Management of Leukemia Ali Al-Ameri 1, Mohamad Cherry 2, Aref Al-Kali 1 and Alessandra Ferrajoli 1,* 1 Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA 2 Department of Internal Medicine, Hematology Oncology section, Oklahoma University Health Sciences Center, 700 N.E. 13th Street, Oklahoma City, OK 74103, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-713-792-2063. Received: 20 September 2010 / Accepted: 18 October 2010 / Published: 18 October 2010 Abstract: This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33. The introduction of rituximab, an anti CD20 monoclonal antibody, had a great impact in the treatment of lymphoproliferative disorders. Gemtuzumab, an anti CD 33 conjugated monoclonal antibody has activity in acute mylegenous leukemia (AML). As this field is undergoing a rapid growth, the years will see an increasing use of monoclonal antibodies in hematological malignancies. Keywords: monoclonal Abs; leukemia; CLL; AML; ALL 1. Introduction In 1900, speaking of monoclonal antibodies (MAbs), Paul Ehrlich proposed that “immunizations such as these which are of great theoretic interest may come to be available for clinical application attacking epithelium new formations, particularly carcinoma by means of specific anti-epithelial sera”[1]. Erlich’s dream came true with the first report of the manufacturing of MAb in 1975 by Kohler and Milstein [2,3].
    [Show full text]
  • 2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
    MEDICAL POLICY – 2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma BCBSA Ref. Policy: 2.03.05 Effective Date: Sept. 1, 2021 RELATED MEDICAL POLICIES: Last Revised: Aug. 3, 2021 5.01.549 Off-Label Use of Drugs and Biologic Agents Replaces: N/A 5.01.550 Pharmacotherapy of Arthropathies 5.01.556 Rituximab: Non-oncologic and Miscellaneous Uses 8.01.533 Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction An antibody is a blood protein. When the immune system detects an unhealthy cell, antibodies attach themselves to a molecule known as an antigen on that unhealthy cell. The antibody then acts as flag for other immune system cells, causing those other immune system cells to swarm to the area and fight the unhealthy cell. Cancer cells can evade the immune system by reproducing very quickly, avoiding detection, or completely blocking the immune system. Monoclonal antibodies are drugs that work with the body’s natural immune response. Monoclonal antibodies are produced in a laboratory and made to specifically attach to the antigens which are typically found in high numbers on cancer cells. This policy describes when treatment with monoclonal antibodies may be approved to treat lymphoma. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals.
    [Show full text]